Media Relations News Releases Year: - Any -202120202019201820172016 Items per page 102550 Apr 17, 2018 Summary ToggleNovartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures Mar 22, 2018 Summary ToggleKymriah™ (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval for certain adults with r/r DLBCL Feb 16, 2018 Summary ToggleNovartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis Feb 16, 2018 Summary ToggleNovartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis Jan 31, 2018 Summary ToggleNovartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah™ in children, young adults with r/r ALL Dec 10, 2017 Summary TogglePrimary analysis results from Novartis pivotal JULIET trial show Kymriah™ (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer Nov 30, 2017 Summary ToggleNovartis’ Cosentyx® is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients Nov 29, 2017 Summary ToggleNovartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab (AMG334) in migraine prevention Nov 10, 2017 Summary ToggleNovartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants Nov 10, 2017 Summary ToggleNovartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness Pagination First page First Previous page Previous … Page 6 Current page 7 Page 8 Page 9 … Next page Next Last page Last
